Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.
Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.
Earns from sales of Anktiva, instilled into the bladder in a urologist's office alongside the standard BCG treatment. Spending far exceeds sales while the launch builds, and the company has been funded largely by chairman Patrick Soon-Shiong, who holds a majority of the shares. The rest of the pipeline is not yet generating sales.
Moat: narrow (IP / patents, regulatory licence). Approved therapy for a specific unmet niche (BCG-unresponsive bladder cancer) ahead of most pipeline rivals.
Headquarters: San Diego, California, United States · Founded: 2014 · Employees: 691
Size ImmunityBio (IBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.13B, the 950th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.70 on 18 Nov 2026.
Performance Over six months the shares fell 16.8%, against +5.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 121.2% over the last twelve months (peer median +8.9%); the operating margin is -150.2% (peer median 15.1%).
Valuation It trades at 44.3× enterprise value to sales against a peer median of 4.8× (2nd most expensive of 19).
Short interest Short interest is 11.9% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $183M | $113M | $14.7M | $622,000 | $240,000 |
| Revenue growth | — | +668% | +2,271% | +159% | — |
| Gross profit | $164M | $97.0M | -$2.81M | -$17.9M | -$24.0M |
| EBITDA | -$258M | -$241M | -$327M | -$343M | -$326M |
| Net income | -$1.11B | -$351M | -$414M | -$583M | -$417M |
| Free cash flow | -$297M | -$309M | -$398M | -$397M | -$416M |
| Capital expenditure | $9.53M | $4.25M | $6.89M | $30.6M | $99.4M |
| Total debt | $1.30B | $845M | $790M | $884M | $725M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ImmunityBio IBRX | $7.13B | -17% | +121% | -150% | 44.3× | n/a |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| UroGen Pharma URGN | $1.46B | -1% | +159% | -12% | 6.3× | n/a |
| CG Oncology CGON | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IBRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.6% | +2.2% | 3rd lowest of 21 |
| 6-month return | -16.8% | +5.9% | 5th lowest of 20 |
| Distance from 52-week high | -46.1% | -14.9% | 4th lowest of 21 |
| Revenue growth (TTM) | +121.2% | +8.9% | highest of 18 |
| Operating margin | -150.2% | 15.1% | 2nd lowest of 19 |
| EV / Sales | 44.3× | 4.8× | 2nd most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | 44.3× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | 64.3× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 5.8× | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 8.6× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | 12.9× | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 7.3× | 23.9% | +16.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 7.3× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% | +7.1% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 2.1× | 2.9% | +6.6% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 1.1× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 4.1× | 25.0% | +10.7% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% | +8.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 1.9× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 3.5× | -11.9% | +4.2% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 5.9× | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% | +7.3% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 7.4× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 4.7× | 27.3% | +9.4% |